Clinical trials
HER 2 Negative Breast Cancer clinical trials
Below are recruiting her 2 negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 914 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04891068RecruitingPhase 2
Pre-surgery low-dose azacitidine for high-risk early breast cancer
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
Chicago, IllinoisAges 18 years+ - NCT04861077RecruitingEarly Phase 1
PET/MRI monitoring for PD-L1–positive triple-negative breast cancer
This early-phase study uses advanced PET/MRI scans to monitor how immunotherapy treatment works in people with triple-negative breast cancer that is PD-L1 positive. It may help doctors better track tumor changes in the body over time.
Birmingham, AlabamaAges 18–75 - NCT04921137RecruitingPhase 4
Testing benefits and side effects of hormone therapy in older breast cancer patients
This study looks at the potential harms and benefits of hormone (endocrine) therapy in people age 70 and older with early-stage, hormone-receptor–positive breast cancer. It may help doctors choose which hormone treatment approach is safest and most helpful for older patients.
Edmonton, AlbertaAges 70 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04771871RecruitingPhase 2
Study tiny RNA changes in triple-negative breast cancer
This trial studies patterns of microRNA (tiny gene-regulating molecules) in women with triple-negative breast cancer. By comparing these microRNA profiles, the study hopes to better understand the disease and potentially guide future treatment choices.
Ile-Ife, OshunAges 18–70 - NCT04768426RecruitingPhase 2
Watching DNA in blood while taking capecitabine after breast cancer
This trial checks how a blood test that looks for cancer DNA (ctDNA) changes during and after you take capecitabine after early triple-negative breast cancer. It aims to see whether these blood test results can help monitor the chance of the cancer coming back.
Stanford, CaliforniaAges 18 years+ - NCT04660435Recruiting
Study how breast cancers resist CDK4/6 inhibitor treatment
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
Prato, TuscanyAges Any age - NCT04677816RecruitingPhase 2
Vitamin D for a better response to chemotherapy
This study tests whether taking high-dose vitamin D before and during chemotherapy helps eliminate more cancer before surgery in people with triple-negative breast cancer who are low in vitamin D.
Winston-Salem, North CarolinaAges 18 years+ - NCT04683679RecruitingPhase 2
Radiation plus pembrolizumab and olaparib for certain breast cancers
This study tests whether adding the drugs pembrolizumab and olaparib (or similar “radiosensitizers”) to radiation can improve outcomes for women with advanced breast cancer that is triple-negative or ER-positive/Her2-negative. It’s designed for cancers that have spread or come back and where radiation is being considered to control disease.
Basking Ridge, New JerseyAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT04589468Recruiting
Exercise for cancer survivors at high risk
This study tests whether a structured exercise program can help prevent cancer from coming back in people who have been treated for certain solid tumors (colorectal, ovarian, lung, or breast cancer). If you've completed surgery and adjuvant therapy within the past 2 years and are currently not exercising much, you may be eligible. Participation involves following an exercise plan and regular check-ins.
Durate, CaliforniaAges 18 years+ - NCT04523857RecruitingPhase 2
Abemaciclib and hydroxychloroquine after breast cancer relapse risk
This Phase 2 trial tests whether abemaciclib plus hydroxychloroquine can kill tiny “leftover” cancer cells in the bone marrow after standard breast cancer treatment. It may help lower the chance of cancer coming back by targeting minimal residual disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04529044RecruitingPhase 2
177Lu-DOTATATE for advanced breast cancer with targeted receptors
This Phase 2 trial tests whether 177Lu-DOTATATE can slow or shrink stage IV or recurrent breast cancer. It targets tumor “receptors” found on scans, using a radioactive medicine that delivers radiation directly to cancer cells.
Portland, OregonAges 18–100 - NCT04521764RecruitingPhase 1
Vaccine for Metastatic Breast Cancer
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+ - NCT04360330Recruiting
MRI study in early breast cancer with specific lab markers
This study tests selected treatment decisions for women with early-stage breast cancer that has certain lab test results. It may help researchers better match care using MRI and tumor marker information.
Miami, FloridaAges 50 years+ - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Tampa, FloridaAges 18 years+ - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT04133077Recruiting
Biobank study using tumor tissue to grow patient tumor models
This study takes small samples of your breast tumor tissue after (or during) treatment and grows them in lab animals to better study breast cancer. It may help researchers test future ideas for treating aggressive breast cancer types like triple-negative or Luminal B.
Clermont-Ferrand, Puy-de-DômeAges 18 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT04084730RecruitingPhase 2
3-day radiation after breast-conserving surgery for certain breast cancers
This trial tests whether a shorter, 3-day course of partial breast radiation after surgery works as well as standard radiation for women with early-stage breast cancer. It may help reduce time in treatment while aiming to keep cancer from coming back in the treated breast area.
Norwalk, ConnecticutAges 45 years+ - NCT03936478RecruitingPhase 2
MRI-guided partial breast radiation in three short treatments
This study tests a faster, targeted type of radiation for early breast cancer, using real-time MRI to help plan and guide treatment. It may help deliver the same cancer-fighting effect while limiting radiation to the rest of the breast.
Madison, WisconsinAges 40 years+
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her 2 negative breast cancer?
- Yes. Clin2 currently lists 914 recruiting her 2 negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her 2 negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her 2 negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.